The p16 (CDKN2A) inactivation—primarily through promoter hypermethylation—represents a hallmark of lung cancer progression, enabling cell cycle dysregulation via CDK4/6-RB pathway activation (89). Here, CDKN2A is linked to lung carcinoma.